Market Synopsis of global Tetanus toxoid vaccine market:
The Tetanus toxoid vaccine market is projected to reach USD 7,236.2 Million by 2030 at 5.9% CAGR during the forecast period 2022-2030.
Tetanus is an infectious disease caused by Clostridium tetani characterized by muscle spasms. The spasms may be very severe and even cause bone fractures. Other symptoms include fever, sweating, headache, trouble swallowing, hypertension etc. About 10% of those infected, die while a large number become incapacitated due to bone fractures. Tetanus toxoid vaccine is an inactive vaccine used to prevent tetanus by developing immunity against the pathogen causing tetanus. The general dosage recommendation is five doses during childhood, with a sixth given during adolescence with additional doses every 10 years. The tetanus vaccine was initially developed in 1924 and has resulted in a 95% decrease in the rate of tetanus in the US and is on the World Health Organization's List of Essential Medicines. The vaccine also is considered very safe even during pregnancy and for those with HIV.
The market restraints of the tetanus toxoid vaccine are redness and pain at the site of injection, fever, and fatigue and muscles pains. Severe allergic reactions are the most serious side effects of the Tetanus toxoid vaccine which occur in less than one in 100,000 people. The market for tetanus toxoid vaccine is bipolar with contractual market having a sizable number of share as compared to the private market. The other market constraints include falling profitability of vaccine manufacturing, huge reduction of tetanus in the developed world which effectively eliminates the need for further vaccination due to herd immunity, side effects associated with vaccines, variability of efficacy of tetanus toxoid vaccine etc.
The low profitability in vaccine manufacturing has reduced incentives for developing vaccines for diseases of the developing world such as tuberculosis and malaria.
Sources: Mayo Clinic, MRFR Analysis.
The global tetanus toxoid vaccine market is segmented on the basis of types, forms and end users. Based on types, the market has been segmented as monovalent tetanus toxoid (TT), diphtheria, tetanus, and pertussis (DTaP), diphtheria and tetanus (DT), tetanus, diphtheria, and pertussis (Tdap) and others. Based on the forms, the market has been segmented as quadrivalent, pentavalent, and hexavalent. Based on the end users, the market has been segmented as biotech and hospitals and clinics, government organizations, research and others.
US accounts for the maximum market share due to greater use of medications and greater expenditure on healthcare. The faster market uptake of new technology and devices in the US is also an important driver of the market for global Tetanus toxoid vaccine. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region is expected to have the most future potential and it is estimated to be led by China and India. The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The regions of Africa are expected to witness a moderate growth due to poor economic and political conditions and poor healthcare penetration.
Key players of Global Tetanus toxoid vaccine market:
Key players profiled in the report are GlaxoSmithKline Plc., Merck & Co. Inc., Pfizer, Inc., Sanofi Pasteur, Inc., AstraZeneca Plc., Bharat Biotech, Shenzhen Kangtai Biological Products, Valeant Pharmaceuticals, Emergent Biosolutions Inc., Astellas Pharma Inc., Panacea Biotec and others. The report for Global Tetanus toxoid vaccine market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
|Market Size||USD 7,236.2 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Types, Forms, End Users|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||GlaxoSmithKline Plc., Merck & Co. Inc., Pfizer, Inc., Sanofi Pasteur, Inc., AstraZeneca Plc., Bharat Biotech, Shenzhen Kangtai Biological Products, Valeant Pharmaceuticals, Emergent Biosolutions Inc., Astellas Pharma Inc., Panacea Biotec|
|Key Market Opportunities||
|Key Market Drivers||
Tetanus toxoid vaccine market CAGR would be 5.9% during the forecast period.
Tetanus toxoid vaccine market valuation would be USD 7,236.2 Million by 2030.
The US would dominate the North American tetanus toxoid vaccine market.
The end users mentioned in the tetanus toxoid vaccine market report are government organizations, research, biotech and hospitals and clinics, and others.
The types discussed in the tetanus toxoid vaccine market report are tetanus, and pertussis (DTaP), monovalent tetanus toxoid (TT), diphtheria, tetanus, diphtheria, and pertussis (Tdap), diphtheria and tetanus (DT), and others.